Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I thought it was impressive tbh. I had my doubts. Certainly thought there was a good chance they’d give some excuse for delaying the FDA process till H2 next year. The fact they’re saying this year shows they’ve stuck to their word, at least for now. FDA process isn’t long so could expect a positive result Q1, maybe Q2 next year. And if that’s the case, well, skys the limit then.
Raising quite a bit above the current price is also very well played
Bunson I would say the 8.80 was definitely a buy. It is not always clear on the trades which is a buy or a sell due to the algorithm that LSE use but by looking at the price it would indicate it was a buy. The problem with this showing red allows the skip rat MM’s a chance to play their games.
On the back of the recent announcement the SP should now be up at least 15p mark. I hope this is reflected in the trades today as it is still a complete bargain at this price.
Messi I believe reading between the lines from Robert’s announcement that FDA should be achieved by early next year which let’s face is not that far away as we are nearly in October. I was very pleased to see the announcement but I wish Robert’s had made some announcement sooner rather than keeping share holders in the dark which has had a major effect on the share price and allowed MM manipulation. I really hope going forward he will learn from this and keep the shareholders & the market more informed on what’s going on with the company, we can clearly see things are moving along in the right direction which should breed confidence. Truspine should never be sitting at this share price. If your reading this Robert’s keep your shareholders informed because as you can see the effect these positive announcements have made already to the SP. onwards and upwards TS.
That 8.80p trade do we think it was a buy or sell? Can’t believe it’s a sell otherwise it’s higher than the previous trade, which was a buy... Never see that before
Glad to finally hear something from TSP - hope the 'Breakthrough Device' application will raise the profile of the product that much more if/when it clears FDA and isn't just sugar coating to illustrate activity and excuse continuous delays. The 10p raise at a premium seems assuring. Still in the bottom drawer waiting for FDA, patience still needed while currently looks like a good entry/top-up point if confident. GLA.
Also worth a reminder that Oberon (part of the group not necessarily Oberon Capital the broker) hold 5.81% so they have some flesh in the game.
So Truspiner investors was I right or was I right nice to hear Bunson being positive . Did I say that we would hear some good news some time soon!!!Good old Ian has at last served up some really positive news for all concerned which was about time ffs.
I hope Payinattn gets on this and give some praise where praise is due.
It is better taking a bit of time to get the FDA spot on see when we hit the market we will hit it running. The raise at 10p above market value is also really positive along with bringing in new brokers Oberon who will steer the ship better than WH Ireland did .
I also said fill your boots at the price as it will start to get back to ipo levels. Onwards and upwards to the Truspine- keep the faith it’s all coming together.
Hmm, does look quite good tbf
In parallel with the 510K application, TruSpine has commissioned Emergo, to prepare and file a submission requesting that the FDA examine the Cervi-LOK™ to be designated as a "Breakthrough Device". This requires a new Q-Sub application which will require additional time to prepare but will confer significant long-term benefits on the Cervi-LOK™ and its commercialisation. This can include higher margin returns through preferred insurance coding and hospital reimbursement.
Breakthrough device sounds really good.
Amazing progress overall. Lots have been done. Oberon active as a broker is very good news as well.
Raise 20% ABOVE the current SP, with Warrants almost 80% ABOVE the current SP. This instils confidence in investors and will provide lots more cash to the company once the SP hits above 15p per share
Funding at 10p?
The following have now been completed since the last update to market in April 2021:
· Testing and design freeze of Cervi-LOK™ product
· Testing and design freeze of Cervi-LOK™ instrumentation
· Completion of three Cadaver Studies
· Appointment of Anthony Swoboda as US Vice President of sales and marketing,
· Appointment of consultant neurosurgeon Nik Patel as a Non-Executive Director
· Appointment of William Lavalle, M.D., as the Chairman of our Medical Advisory board